Investigational analgesic drug
Pharmaceutical compound
DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]
See also
References
- ^ a b Martz L (2014). “Nav-i-gating antibodies for pain”. Science-Business EXchange. 7 (23): 662. doi:10.1038/scibx.2014.662. ISSN 1945-3477.
- ^ a b Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). “Recent progress in sodium channel modulators for pain”. Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
External links
- “DSP-2230”. AdisInsight. Springer Nature Switzerland AG.
| Calcium |
| ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Potassium |
| ||||||||||||||||||||||||
| Sodium |
| ||||||||||||||||||||||||
| Chloride |
| ||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||